Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.64 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.56 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.56 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.56 |
| ▸ | STRADA | Q7RTN6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29594751 | 0.89 | MAPK14 (0.66) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL5861996 | 0.89 | MAPK14 (0.66) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL29594719 | 0.88 | MAPK14 (0.64) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL5862045 | 0.88 | MAPK14 (0.64) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL29594200 | 0.85 | MAPK14 (0.65) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL5863026 | 0.85 | MAPK14 (0.65) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL29593356 | 0.84 | MAPK14 (0.64) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL5862556 | 0.84 | MAPK14 (0.64) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL29593567 | 0.84 | MAPK14 (0.64) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL5862110 | 0.84 | MAPK14 (0.64) | MAPK14ROCK2MAPK12MAPK11STRADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885ROCK2 819/4885MAPK12 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.